AstraZeneca's cancer drug, datopotamab deruxtecan, failed to meet targets in a Phase 3 trial, clouding the possibility of approval from the U.S. Food and Drug Administration. Shares were down 1.2% at ...

A new meta-study shows that Black women are 40% more likely than white women to die from all types of breast cancer, and ...

During a Case-Based Roundtable® event, Virginia F. Borges, MD, MMSc, discussed treatment selection for a patient with ER+, ...

Morgen Chesonis-Gonzalez thought she would be fine skipping her yearly mammogram - but a persistent pain convinced her otherwise.

In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates ...

This week's topics include youth, opioids and emergency medical services (EMS), good news for women with triple-negative breast cancer, a lack of benefit for rapid malaria tests, and risk associated ...

IBCN annual meeting included a keynote lecture by Dr. Niko Beerenwinkel discussing inferring tumor evolution from single-cell data. Although the majority of work has been done in other cancers (ie.

I originally wasn’t going to get one because I was still breastfeeding. Thank goodness I did, because I had triple-negative ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...